var data={"title":"Thoracic positron emission tomography","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Thoracic positron emission tomography</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/contributors\" class=\"contributor contributor_credentials\">Paul Stark, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/contributors\" class=\"contributor contributor_credentials\">Nestor L Muller, MD, PhD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/contributors\" class=\"contributor contributor_credentials\">Geraldine Finlay, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/contributors\" class=\"contributor contributor_credentials\">Susanna I Lee, MD, PhD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 09, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Positron emission tomography (PET) allows in vivo imaging of metabolic, physiologic, and pathologic processes. It has been used as a research tool for many years, and has evolved into a clinically indispensable imaging examination. The increased clinical use is a consequence of regional commercial radiopharmacies being more able to supply hospitals throughout the country with radiopharmaceuticals, while the equipment has become more robust and financially more affordable. Traditional PET scanners with an array of several thousand ring detectors can be replaced by traditional two-headed single photon emission computed tomography (SPECT) gamma cameras that have been retrofitted with coincidence detectors to allow 18-fluoro-2-deoxyglucose (FDG)-PET imaging. Many PET scanners are being replaced by integrated whole-body PET and computed tomography scanners <span class=\"nowrap\">(PET/CT</span> scanners) [<a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/1\" class=\"abstract_t\">1</a>], while integrated, hybrid PET and magnetic resonance <span class=\"nowrap\">(PET/MR)</span> scanners are being introduced as well [<a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/2,3\" class=\"abstract_t\">2,3</a>].</p><p>Technical issues (ie, radionuclides, technique, sources of error) and the indications for thoracic PET imaging are reviewed here. The use of PET scanning in the evaluation of solitary pulmonary nodules or lung cancer staging is discussed separately. (See <a href=\"topic.htm?path=computed-tomographic-and-positron-emission-tomographic-scanning-of-pulmonary-nodules\" class=\"medical medical_review\">&quot;Computed tomographic and positron emission tomographic scanning of pulmonary nodules&quot;</a> and <a href=\"topic.htm?path=imaging-of-lung-cancer\" class=\"medical medical_review\">&quot;Imaging of lung cancer&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">TECHNICAL ISSUES</span></p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Radionuclides</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Positron-emitting radionuclides are produced in a cyclotron (eg, oxygen-15, nitrogen-13, carbon-11, and fluorine-18) or by a generator (eg, rubidium-82, copper-62). Fluorine-18 is one such radionuclide that is produced by proton bombardment of oxygen-18 in a cyclotron. When it is bound to a D-glucose analog, it forms 18-fluoro-2-deoxyglucose (FDG), which is the most commonly used radionuclide in thoracic positron emission tomography (PET).</p><p>FDG is transported into cells where it is phosphorylated to form FDG-6-phosphate, which remains trapped temporarily because it is not further metabolized by the enzyme glucose-6-phosphatase, nor is it easily extruded from the cell. The fluorine-18 emits positrons as it decays, which travel a short distance before they are annihilated by electrons, resulting in the emission of two 0.511 MeV photons oriented at 180 degrees to each other. These events are registered when the photons collide with the sodium iodide or bismuth germanate contained within the scintillation detectors that surround the patient (<a href=\"image.htm?imageKey=PULM%2F59100%7EPULM%2F70885\" class=\"graphic graphic_diagnosticimage graphicRef59100 graphicRef70885 \">image 1A-B</a>), thereby triggering an electronic pulse within the scintillation crystal. Three-dimensional localization of the decay is possible because of the coincidence circuitry that detects the annihilation radiation [<a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/4\" class=\"abstract_t\">4</a>]. The end result is measurement of the distribution of FDG throughout the body. The FDG is eventually extruded from the cell, filtered by the glomerulus without being resorbed in the proximal convoluted tubule, and excreted in the urine.</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Technique</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>During a PET scan, the patient lies within a scanner that consists of a moving table and gantry, reminiscent of the equipment used for computed tomography (CT). Before the administration of FDG, scans are obtained using a rotating germanium-68 pinpoint source. This process is called attenuation correction and its purpose is to adjust for the decrement of positron-related radiation caused by soft tissues of varying electron densities (<a href=\"image.htm?imageKey=PULM%2F66420\" class=\"graphic graphic_figure graphicRef66420 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/5\" class=\"abstract_t\">5</a>]. FDG is injected intravenously using a dose of 10 to 20 mCi (370 to 740 MBq) and then multiple (ie, 30 to 45) axial (ie, cross-sectional) images are obtained. A cross-sectional, axial field of view of 16 to 20 cm and a spatial resolution of 5 mm are achieved at full width half maximum. Finally, axial, coronal, and sagittal projections are viewed on a workstation and whole body images can be generated.</p><p>PET images and CT images obtained from separate studies are sometimes combined, in an effort to incorporate the detailed anatomical information generated by CT scans with the metabolic localization of PET scans. However, the results are often difficult to interpret due to respiratory variability and variations in the patient's position. Integrated <span class=\"nowrap\">PET/CT</span> scanners or <span class=\"nowrap\">PET/MR</span> scanners avoid these pitfalls by fusing images obtained in tandem from PET and CT or PET and MR (<a href=\"image.htm?imageKey=PULM%2F81038\" class=\"graphic graphic_diagnosticimage graphicRef81038 \">image 2</a> and <a href=\"image.htm?imageKey=PULM%2F70273\" class=\"graphic graphic_diagnosticimage graphicRef70273 \">image 3</a>).</p><p>During the acquisition of an integrated <span class=\"nowrap\">PET/CT</span> scan, the CT is performed first. FDG is then injected intravenously and the PET is performed 40 to 60 minutes later [<a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/6,7\" class=\"abstract_t\">6,7</a>]. A major advantage of integrated <span class=\"nowrap\">PET/CT</span> is that it reduces the examination time by 30 percent compared to the time that it takes to acquire each study separately (whole body integrated <span class=\"nowrap\">PET/CT</span> images can be obtained within 30 minutes) [<a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/8\" class=\"abstract_t\">8</a>]. This time savings is achieved because integrated <span class=\"nowrap\">PET/CT</span> eliminates the need for the separate attenuation correction step with the germanium-68 pinpoint source, described above, since the attenuation maps created using CT scan data can be used for this purpose. Integrated or hybrid whole-body <span class=\"nowrap\">MR/PET</span> scanners are also feasible and provide diagnostic image quality in the assessment of pulmonary masses or staging of lung cancer [<a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/2,3\" class=\"abstract_t\">2,3</a>].</p><p class=\"headingAnchor\" id=\"H6684631\"><span class=\"h2\">Clinical role</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical role of thoracic PET is related to the fact that aerobic glycolysis is amplified in tumor cells (ie, the Warburg effect) [<a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/9\" class=\"abstract_t\">9</a>]. To facilitate aerobic glycolysis, more glucose transporters (eg, Gluc-1) are expressed on the surface of tumor cells, leading to increased transport of FDG into the tumor cells. In addition, an increased concentration of hexokinase is expressed within the cell, leading to enhanced intracellular trapping of the FDG [<a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/10-13\" class=\"abstract_t\">10-13</a>]. The result is magnified uptake and accumulation of FDG within tumor cells, creating discrete, selected foci of FDG uptake that can be visualized on the PET scan. Quantification of the amount of radioactivity in a voxel is obtained by calculating the standardized uptake value (SUV). The SUV equals the mean region of interest <span class=\"nowrap\">(mCi/mL)</span> divided by the administered activity (mCi per body weight). An SUV exceeding 2.5 raises the possibility of malignant disease [<a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/6,7\" class=\"abstract_t\">6,7</a>]. Additional parameters, like metabolic tumor volume (MTV) and total lesion glycolysis (TLG), can be utilized and may have prognostic value in the assessment of non-small cell lung cancer [<a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/14\" class=\"abstract_t\">14</a>]. TLG is the product of MTV and maximal SUV.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Sources of error</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The likelihood of an abnormal integrated <span class=\"nowrap\">PET/CT</span> scan in a patient with malignancy (ie, the sensitivity) is close to 90 percent, while the likelihood of a normal integrated <span class=\"nowrap\">PET/CT</span> scan in a patient without malignancy (ie, the specificity) is approximately 80 percent [<a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/15\" class=\"abstract_t\">15</a>]. As a consequence, false positive results (ie, 1-specificity) are more common than false negative results (ie, 1-sensitivity). The specificity is lower than the sensitivity because inflammatory and granulomatous lesions can yield a positive FDG-PET scan.</p><p>False positive results are generally due to metabolically active infectious or inflammatory lesions, which can produce substantial FDG accumulation [<a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/16\" class=\"abstract_t\">16</a>]. Examples include rheumatoid nodules, tuberculous granulomata, fungal granulomata, pneumonia, empyema, drug toxicity, surgical procedures, including inflammation at the site of incision or dissection, inflammation from vascular compromise or surgical retraction, surgical transposition of structures with physiologic FDG avidity (such as ovaries or testes), pleurodesis inflammation [<a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/17\" class=\"abstract_t\">17</a>], and sarcoidosis. Radiation pneumonia may also lead to increased FDG accumulation; therefore, FDG-PET should not be performed until three months after the completion of radiation therapy to reduce the likelihood of false positive results [<a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/18\" class=\"abstract_t\">18</a>]. All of these conditions recruit inflammatory cells (eg, histiocytes, plasma cells, and lymphocytes), which have a high metabolic rate and yield an increased uptake of FDG [<a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/19\" class=\"abstract_t\">19</a>]. In geographic regions where infections with tuberculosis or fungi (eg, histoplasmosis, coccidioidomycosis, and blastomycosis) are endemic, FDG-PET may have a lower specificity for the diagnosis of malignant solitary pulmonary nodules.</p><p>False positive lesions are not limited to infectious or inflammatory lesions. Brown adipose tissue that is located at the base of the neck, in the supraclavicular region, in the superior mediastinum, and in the upper abdomen of adult humans can exhibit strong uptake of FDG and cause false positive results [<a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/20-22\" class=\"abstract_t\">20-22</a>]. Brown fat is metabolically active and uses glucose to uncouple the electron transport chain for thermogenesis. Atrial natriuretic peptides and B-type natriuretic peptide stimulate the synthesis and activity of brown fat [<a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/23\" class=\"abstract_t\">23</a>]. Treatment with benzodiazepines prior to FDG-PET reduces the sympathetic tone, which keeps the patient warm, reduces the metabolism of brown fat, and decreases the likelihood of false positive results [<a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/7,19\" class=\"abstract_t\">7,19</a>]. Normal or hyperplastic thymic tissue can also be glucose avid, which can lead to high uptake of FDG in the anterior mediastinum [<a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/24\" class=\"abstract_t\">24</a>]. Other regions of physiological FDG uptake in the chest that can lead to false positive results include the heart and breast tissue [<a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/7\" class=\"abstract_t\">7</a>].</p><p>False negative results are less frequent, but generally occur in three clinical settings [<a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/5\" class=\"abstract_t\">5</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Tumors with slow growth and with low metabolism &ndash; Tumors with relatively low metabolic activities may fail to concentrate enough FDG to be detected, as has been reported with selected cases of bronchioloalveolar cell carcinomas, preferentially called adenocarcinoma in situ, well differentiated, minimally invasive adenocarcinomas, and carcinoid tumors [<a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/25-29\" class=\"abstract_t\">25-29</a>]. Rarely, metastatic lesions from renal cell, prostate, or testicular cancers may be devoid of detectable amounts of FDG.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Small tumors &ndash; Small tumors (&lt;7 mm in diameter) may not be detected because the amount of FDG uptake by the lesions is below the resolution threshold of FDG-PET scanners [<a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/30\" class=\"abstract_t\">30</a>]. PET scanners that use single photon emission computed tomography (SPECT) cameras have a lower sensitivity than dedicated FDG-PET scanners and are not state of the art anymore.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hyperglycemia &ndash; An elevated serum glucose level decreases intracellular FDG uptake because the FDG and glucose compete for the same cell surface receptor [<a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/31\" class=\"abstract_t\">31</a>]. This competition is more pronounced in the presence of acute hyperglycemia. A reasonable (albeit unstudied) approach that may minimize this confounding factor is for patients to follow a low carbohydrate diet beginning 24 hours prior to PET scanning and to adhere to a four-hour fasting period (except water) immediately prior to the study. The management of oral hypoglycemic agents and insulin in fasting patients is discussed separately. (See <a href=\"topic.htm?path=perioperative-management-of-blood-glucose-in-adults-with-diabetes-mellitus#H9\" class=\"medical medical_review\">&quot;Perioperative management of blood glucose in adults with diabetes mellitus&quot;, section on 'Type 2 diabetes treated with oral hypoglycemic agents/noninsulin injectables'</a> and <a href=\"topic.htm?path=perioperative-management-of-blood-glucose-in-adults-with-diabetes-mellitus#H10\" class=\"medical medical_review\">&quot;Perioperative management of blood glucose in adults with diabetes mellitus&quot;, section on 'Type 1 or insulin-treated type 2 diabetes'</a>.).</p><p/><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">INDICATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The use of thoracic 18-fluoro-2-deoxyglucose (FDG)-PET and integrated <span class=\"nowrap\">PET/computed</span> tomography <span class=\"nowrap\">(PET/CT)</span> have been best studied and most widely accepted in four clinical settings [<a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/32-34\" class=\"abstract_t\">32-34</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Solitary pulmonary nodules &ndash; FDG-PET or integrated <span class=\"nowrap\">PET/CT</span> may help distinguish benign from malignant pulmonary nodules (<a href=\"image.htm?imageKey=PULM%2F75774%7EPULM%2F55811%7EPULM%2F69851%7EPULM%2F58095%7EPULM%2F82372%7EPULM%2F59657%7EPULM%2F73552\" class=\"graphic graphic_diagnosticimage graphicRef75774 graphicRef55811 graphicRef69851 graphicRef58095 graphicRef82372 graphicRef59657 graphicRef73552 \">image 4A-G</a>). The role of FDG-PET and integrated <span class=\"nowrap\">PET/CT</span> in the evaluation of solitary pulmonary nodules is discussed separately. (See <a href=\"topic.htm?path=diagnostic-evaluation-of-the-incidental-pulmonary-nodule\" class=\"medical medical_review\">&quot;Diagnostic evaluation of the incidental pulmonary nodule&quot;</a> and <a href=\"topic.htm?path=computed-tomographic-and-positron-emission-tomographic-scanning-of-pulmonary-nodules\" class=\"medical medical_review\">&quot;Computed tomographic and positron emission tomographic scanning of pulmonary nodules&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lung cancer staging &ndash; FDG-PET, integrated <span class=\"nowrap\">PET/CT,</span> and integrated <span class=\"nowrap\">PET/MR</span> may help identify tumor tissue that has metastasized beyond the primary lesion, thus facilitating clinical-radiological staging (<a href=\"image.htm?imageKey=PULM%2F59658%7EPULM%2F79073%7EPULM%2F72484%7EPULM%2F68761%7EPULM%2F57052%7EPULM%2F78739%7EPULM%2F61004\" class=\"graphic graphic_diagnosticimage graphicRef59658 graphicRef79073 graphicRef72484 graphicRef68761 graphicRef57052 graphicRef78739 graphicRef61004 \">image 5A-G</a>). The role of FDG-PET and integrated <span class=\"nowrap\">PET/CT</span> in the staging of non-small cell lung cancer is discussed separately. (See <a href=\"topic.htm?path=imaging-of-lung-cancer\" class=\"medical medical_review\">&quot;Imaging of lung cancer&quot;</a> and <a href=\"topic.htm?path=overview-of-the-initial-evaluation-diagnosis-and-staging-of-patients-with-suspected-lung-cancer\" class=\"medical medical_review\">&quot;Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Surveillance for lung cancer recurrence &ndash; FDG-PET or integrated <span class=\"nowrap\">PET/CT</span> can be helpful in the follow-up of patients after initial therapy in order to detect or exclude recurrent tumor. It may assist in the differentiation of recurrent or persistent malignant disease from changes caused by radiation therapy or surgery. FDG-PET and integrated <span class=\"nowrap\">PET/CT</span> have greater sensitivity and specificity for detecting recurrence of tumor in a previously irradiated part of the body than either CT or MRI alone [<a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/35-38\" class=\"abstract_t\">35-38</a>]. Increased uptake of FDG beyond eight weeks after the completion of radiation therapy suggests recurrent or persistent tumor, rather than an effect of radiation therapy.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Evaluation for metastatic esophageal cancer &ndash; Integrated <span class=\"nowrap\">PET/CT</span> may identify metastatic disease that has eluded other imaging modalities [<a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/7,39,40\" class=\"abstract_t\">7,39,40</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clinical management of patients with breast cancer [<a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/41\" class=\"abstract_t\">41</a>].</p><p/><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Positron emission tomography (PET) plays an integral role in the detection of malignant disease. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above and <a href=\"#H6684631\" class=\"local\">'Clinical role'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>During a traditional PET scan, the patient lies within a scanner that consists of a moving table and gantry. 18-fluoro-2-deoxyglucose (FDG) is injected intravenously and multiple sequential images are obtained. Axial, coronal, sagittal, and whole body images can then be viewed on a workstation. In contrast, integrated PET and computed tomography <span class=\"nowrap\">(PET/CT)</span> scanners fuse images obtained from PET and CT performed in tandem, combining the detailed anatomical information generated by CT scans with the metabolic localization of PET scans. (See <a href=\"#H3\" class=\"local\">'Radionuclides'</a> above and <a href=\"#H4\" class=\"local\">'Technique'</a> above.) Early experience with hybrid <span class=\"nowrap\">PET/MR</span> scanners is being accrued.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The clinical role of thoracic PET is based upon the enhanced uptake and accumulation of FDG within tumor cells, creating discrete foci of FDG-induced radioactivity that can be visualized on the PET scan. Quantification of the amount of radioactivity in a voxel is obtained by calculating the standardized uptake value (SUV). An SUV exceeding 2.5 raises the possibility of malignant disease. (See <a href=\"#H6684631\" class=\"local\">'Clinical role'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>False positive results are generally due to metabolically active infectious or inflammatory lesions, but they may also be due to metabolically active brown fat or thymic tissue. False negative results are typically a consequence of a tumor with low metabolic activity, a small tumor, or hyperglycemia. (See <a href=\"#H5\" class=\"local\">'Sources of error'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Indications for PET include distinguishing benign from malignant solitary pulmonary nodules, staging lung cancer, surveying for recurrent lung cancer, evaluating for metastatic esophageal cancer and managing breast cancer. (See <a href=\"#H6\" class=\"local\">'Indications'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/1\" class=\"nounderline abstract_t\">Blodgett TM, Meltzer CC, Townsend DW. PET/CT: form and function. Radiology 2007; 242:360.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/2\" class=\"nounderline abstract_t\">Schwenzer NF, Schraml C, M&uuml;ller M, et al. Pulmonary lesion assessment: comparison of whole-body hybrid MR/PET and PET/CT imaging--pilot study. Radiology 2012; 264:551.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/3\" class=\"nounderline abstract_t\">Ohno Y, Koyama H, Yoshikawa T, et al. Three-way Comparison of Whole-Body MR, Coregistered Whole-Body FDG PET/MR, and Integrated Whole-Body FDG PET/CT Imaging: TNM and Stage Assessment Capability for Non-Small Cell Lung Cancer Patients. Radiology 2015; 275:849.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/4\" class=\"nounderline abstract_t\">DeGrado TR, Turkington TG, Williams JJ, et al. Performance characteristics of a whole-body PET scanner. J Nucl Med 1994; 35:1398.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/5\" class=\"nounderline abstract_t\">Lowe VJ, Naunheim KS. Positron emission tomography in lung cancer. Ann Thorac Surg 1998; 65:1821.</a></li><li class=\"breakAll\">Mettler FA Jr, Guiberteau MJ. Essentials of Nuclear Medicine Imaging, 5th ed, Saunders, Philadelphia 2005.</li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/7\" class=\"nounderline abstract_t\">O'Donnell JS, Rini J, Chusid J, Shah R. Abnormal Uptake on PET/CT: Imitators of Malignancy in Thoracic Imaging. Contemporary Diagnostic Radiology 2011; 34:1.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/8\" class=\"nounderline abstract_t\">von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology 2006; 238:405.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/9\" class=\"nounderline abstract_t\">Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004; 4:891.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/10\" class=\"nounderline abstract_t\">Nolop KB, Rhodes CG, Brudin LH, et al. Glucose utilization in vivo by human pulmonary neoplasms. Cancer 1987; 60:2682.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/11\" class=\"nounderline abstract_t\">Wahl RL, Hutchins GD, Buchsbaum DJ, et al. 18F-2-deoxy-2-fluoro-D-glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron-emission tomography. Cancer 1991; 67:1544.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/12\" class=\"nounderline abstract_t\">Hatanaka M. Transport of sugars in tumor cell membranes. Biochim Biophys Acta 1974; 355:77.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/13\" class=\"nounderline abstract_t\">Langen KJ, Braun U, Rota Kops E, et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med 1993; 34:355.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/14\" class=\"nounderline abstract_t\">Chen HH, Chiu NT, Su WC, et al. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology 2012; 264:559.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/15\" class=\"nounderline abstract_t\">Gould MK, Maclean CC, Kuschner WG, et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001; 285:914.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/16\" class=\"nounderline abstract_t\">Roberts PF, Follette DM, von Haag D, et al. Factors associated with false-positive staging of lung cancer by positron emission tomography. Ann Thorac Surg 2000; 70:1154.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/17\" class=\"nounderline abstract_t\">Ulaner GA, Lyall A. Identifying and distinguishing treatment effects and complications from malignancy at FDG PET/CT. Radiographics 2013; 33:1817.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/18\" class=\"nounderline abstract_t\">Choi YW, Munden RF, Erasmus JJ, et al. Effects of radiation therapy on the lung: radiologic appearances and differential diagnosis. Radiographics 2004; 24:985.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/19\" class=\"nounderline abstract_t\">Asad S, Aquino SL, Piyavisetpat N, Fischman AJ. False-positive FDG positron emission tomography uptake in nonmalignant chest abnormalities. AJR Am J Roentgenol 2004; 182:983.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/20\" class=\"nounderline abstract_t\">Cypess AM, Lehman S, Williams G, et al. Identification and importance of brown adipose tissue in adult humans. N Engl J Med 2009; 360:1509.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/21\" class=\"nounderline abstract_t\">Virtanen KA, Lidell ME, Orava J, et al. Functional brown adipose tissue in healthy adults. N Engl J Med 2009; 360:1518.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/22\" class=\"nounderline abstract_t\">Cronin CG, Prakash P, Daniels GH, et al. Brown fat at PET/CT: correlation with patient characteristics. Radiology 2012; 263:836.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/23\" class=\"nounderline abstract_t\">Wang TJ. The natriuretic peptides and fat metabolism. N Engl J Med 2012; 367:377.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/24\" class=\"nounderline abstract_t\">Ferdinand B, Gupta P, Kramer EL. Spectrum of thymic uptake at 18F-FDG PET. Radiographics 2004; 24:1611.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/25\" class=\"nounderline abstract_t\">Erasmus JJ, McAdams HP, Patz EF Jr, et al. Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR Am J Roentgenol 1998; 170:1369.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/26\" class=\"nounderline abstract_t\">Higashi K, Ueda Y, Seki H, et al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med 1998; 39:1016.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/27\" class=\"nounderline abstract_t\">Kim BT, Kim Y, Lee KS, et al. Localized form of bronchioloalveolar carcinoma: FDG PET findings. AJR Am J Roentgenol 1998; 170:935.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/28\" class=\"nounderline abstract_t\">Jadvar H, Segall GM. False-negative fluorine-18-FDG PET in metastatic carcinoid. J Nucl Med 1997; 38:1382.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/29\" class=\"nounderline abstract_t\">Nishino M, Hatabu H, Johnson BE, McLoud TC. State of the art: Response assessment in lung cancer in the era of genomic medicine. Radiology 2014; 271:6.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/30\" class=\"nounderline abstract_t\">Lowe VJ, Fletcher JW, Gobar L, et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 1998; 16:1075.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/31\" class=\"nounderline abstract_t\">Torizuka T, Clavo AC, Wahl RL. Effect of hyperglycemia on in vitro tumor uptake of tritiated FDG, thymidine, L-methionine and L-leucine. J Nucl Med 1997; 38:382.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/32\" class=\"nounderline abstract_t\">Erasmus JJ, McAdams HP, Patz EF Jr, et al. Thoracic FDG PET: state of the art. Radiographics 1998; 18:5.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/33\" class=\"nounderline abstract_t\">Knight SB, Delbeke D, Stewart JR, Sandler MP. Evaluation of pulmonary lesions with FDG-PET. Comparison of findings in patients with and without a history of prior malignancy. Chest 1996; 109:982.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/34\" class=\"nounderline abstract_t\">Patz EF Jr, Goodman PC. Positron emission tomography imaging of the thorax. Radiol Clin North Am 1994; 32:811.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/35\" class=\"nounderline abstract_t\">Mac Manus MP, Hicks RJ, Ball DL, et al. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer 2001; 92:886.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/36\" class=\"nounderline abstract_t\">Mac Manus MP, Hicks RJ, Matthews JP, et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2003; 21:1285.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/37\" class=\"nounderline abstract_t\">Bury T, Corhay JL, Duysinx B, et al. Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer. Eur Respir J 1999; 14:1376.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/38\" class=\"nounderline abstract_t\">Keidar Z, Haim N, Guralnik L, et al. PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management. J Nucl Med 2004; 45:1640.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/39\" class=\"nounderline abstract_t\">Bruzzi JF, Munden RF, Truong MT, et al. PET/CT of esophageal cancer: its role in clinical management. Radiographics 2007; 27:1635.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/40\" class=\"nounderline abstract_t\">Castillo R, Pham N, Castillo E, et al. Pre-Radiation Therapy Fluorine 18 Fluorodeoxyglucose PET Helps Identify Patients with Esophageal Cancer at High Risk for Radiation Pneumonitis. Radiology 2015; 275:822.</a></li><li><a href=\"https://www.uptodate.com/contents/thoracic-positron-emission-tomography/abstract/41\" class=\"nounderline abstract_t\">Groheux D, Espi&eacute; M, Giacchetti S, Hindi&eacute; E. Performance of FDG PET/CT in the clinical management of breast cancer. Radiology 2013; 266:388.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 6975 Version 12.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H7\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">TECHNICAL ISSUES</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Radionuclides</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Technique</a></li><li><a href=\"#H6684631\" id=\"outline-link-H6684631\">Clinical role</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Sources of error</a></li></ul></li><li><a href=\"#H6\" id=\"outline-link-H6\">INDICATIONS</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PULM/6975|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/59100\" class=\"graphic graphic_diagnosticimage\">- RLL BAC CT</a></li><li><a href=\"image.htm?imageKey=PULM/70885\" class=\"graphic graphic_diagnosticimage\">- RLL BAC PET</a></li><li><a href=\"image.htm?imageKey=PULM/81038\" class=\"graphic graphic_diagnosticimage\">- FDG PET CT lung</a></li><li><a href=\"image.htm?imageKey=PULM/70273\" class=\"graphic graphic_diagnosticimage\">- FDG PET CT axilla</a></li><li><a href=\"image.htm?imageKey=PULM/75774\" class=\"graphic graphic_diagnosticimage\">- RUL SPN PA</a></li><li><a href=\"image.htm?imageKey=PULM/55811\" class=\"graphic graphic_diagnosticimage\">- RUL SPN PET</a></li><li><a href=\"image.htm?imageKey=PULM/69851\" class=\"graphic graphic_diagnosticimage\">- Benign granuloma PA</a></li><li><a href=\"image.htm?imageKey=PULM/58095\" class=\"graphic graphic_diagnosticimage\">- Benign granuloma CT</a></li><li><a href=\"image.htm?imageKey=PULM/82372\" class=\"graphic graphic_diagnosticimage\">- Benign granuloma PET</a></li><li><a href=\"image.htm?imageKey=PULM/59657\" class=\"graphic graphic_diagnosticimage\">- RLL nodule CT</a></li><li><a href=\"image.htm?imageKey=PULM/73552\" class=\"graphic graphic_diagnosticimage\">- RLL nodule PET</a></li><li><a href=\"image.htm?imageKey=PULM/59658\" class=\"graphic graphic_diagnosticimage\">- Superior sulcus PA</a></li><li><a href=\"image.htm?imageKey=PULM/79073\" class=\"graphic graphic_diagnosticimage\">- Superior sulcus CT</a></li><li><a href=\"image.htm?imageKey=PULM/72484\" class=\"graphic graphic_diagnosticimage\">- Superior sulcus PET</a></li><li><a href=\"image.htm?imageKey=PULM/68761\" class=\"graphic graphic_diagnosticimage\">- Central lung tumor PA</a></li><li><a href=\"image.htm?imageKey=PULM/57052\" class=\"graphic graphic_diagnosticimage\">- Central lung tumor CT</a></li><li><a href=\"image.htm?imageKey=PULM/78739\" class=\"graphic graphic_diagnosticimage\">- Central lung tumor PET</a></li><li><a href=\"image.htm?imageKey=PULM/61004\" class=\"graphic graphic_diagnosticimage\">- Right lung tumor PET scan</a></li></ul></li><li><div id=\"PULM/6975|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/66420\" class=\"graphic graphic_figure\">- Attenuation of PET emission</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=computed-tomographic-and-positron-emission-tomographic-scanning-of-pulmonary-nodules\" class=\"medical medical_review\">Computed tomographic and positron emission tomographic scanning of pulmonary nodules</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnostic-evaluation-of-the-incidental-pulmonary-nodule\" class=\"medical medical_review\">Diagnostic evaluation of the incidental pulmonary nodule</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=imaging-of-lung-cancer\" class=\"medical medical_review\">Imaging of lung cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-initial-evaluation-diagnosis-and-staging-of-patients-with-suspected-lung-cancer\" class=\"medical medical_review\">Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=perioperative-management-of-blood-glucose-in-adults-with-diabetes-mellitus\" class=\"medical medical_review\">Perioperative management of blood glucose in adults with diabetes mellitus</a></li></ul></div></div>","javascript":null}